Ratings Evogene Ltd. Nasdaq

Equities

EVGN

IL0011050551

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-13 EDT			5-day change	1st Jan Change
0.6561 ^USD	-0.62%		-3.51%	-21.89%

05-23	Earnings Flash (EVGN) EVOGENE Posts Q1 Revenue $4.2M, vs. Street Est of $3.5M	MT
05-23	Evogene Ltd. Provides Revenue Guidance for the Year 2024	CI

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
EVOGENE LTD.	-21.89%	33.71M	-	-
MODERNA, INC.	+46.03%	55.66B		B-
IQVIA HOLDINGS INC.	-7.53%	38.98B		B
LONZA GROUP AG	+36.30%	38.8B		A
CELLTRION, INC.	-9.38%	27.32B		C
ICON PUBLIC LIMITED COMPANY	+12.31%	26.29B		B-
ALNYLAM PHARMACEUTICALS, INC.	-16.38%	20.25B		B
UNITED THERAPEUTICS CORPORATION	+30.79%	12.76B		B+
MEDPACE HOLDINGS, INC.	+28.57%	12.18B		C+
BIO-TECHNE CORPORATION	-0.36%	12.12B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes